Co-Authors
This is a "connection" page, showing publications co-authored by Robert Landewé and Sofia Ramiro.
Connection Strength
6.036
-
Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Kaklamanos et al. Ann Rheum Dis. 2021 Apr 26.
Score: 0.942
-
Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by De Santis et al. Ann Rheum Dis. 2021 Feb 16.
Score: 0.930
-
Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Charles. Ann Rheum Dis. 2021 Feb 15.
Score: 0.930
-
Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study'' by Calvo-Aranda et al. Ann Rheum Dis. 2020 Dec 14.
Score: 0.918
-
Response to: 'High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab' by Conticini et al. Ann Rheum Dis. 2020 Aug 19.
Score: 0.898
-
Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. Ann Rheum Dis. 2020 09; 79(9):1143-1151.
Score: 0.893
-
Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study'' by Klopfenstein et al. Ann Rheum Dis. 2021 Jun 23.
Score: 0.238
-
Response to 'Neither earlier not late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study' by Moiseev et al. Ann Rheum Dis. 2020 Oct 30.
Score: 0.228
-
Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation. Ann Rheum Dis. 2021 10; 80(10):1362-1363.
Score: 0.059